Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.
Batch number on every vial
Published Certificates of Analysis
Purity verified by third-party testing
Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.
Retatrutide (5 mg) is a synthetic peptide engineered to engage both glucagon-like peptide-1 (GLP-1) and glucagon-related signaling pathways. It incorporates an aminoisobutyric acid (Aib) substitution and a lipid side chain to enhance stability and receptor interaction in experimental settings.
Supplied as a lyophilized powder in a 5 mg vial, confirmed for identity and purity via HPLC and mass spectrometry, Retatrutide is studied in metabolic and endocrine research models. Its research has focused on metabolic signaling, glucose regulation, appetite-related pathways, and energy balance in preclinical and early-stage clinical research models.
For laboratory research use only.
Retatrutide is studied for its role in metabolic regulation through simultaneous activation of multiple hormone pathways. This triple agonist approach is used to evaluate how combined signaling influences energy intake, expenditure, and nutrient metabolism.
Research has focused on several biological areas, including:
Beyond metabolic endpoints, research extends to organ-specific observations, including responses in kidney and liver tissue, as well as broader physiological adaptations to changes in energy balance.
Preclinical and clinical research studies have reported a range of dosing strategies; all findings below are experimental and should not be interpreted as established clinical outcomes.
In preclinical studies, retatrutide has been administered at doses around 10 nmol/kg, often over periods ranging from several days to weeks. These studies typically involve controlled dietary conditions, such as high-fat or high-sugar diets, to evaluate metabolic responses.
Findings include:
Comparative studies have evaluated retatrutide alongside other metabolic peptides, noting differences in outcomes related to body weight, glycemic markers, and organ-specific responses. These comparisons help understand how multi-receptor activation differs from single- or dual-pathway approaches.
In early-phase human studies, once-weekly dosing strategies have been explored, with pharmacokinetic data suggesting a relatively extended half-life, consistent with less frequent administration intervals in research protocols. Clinical research has reported dose-dependent changes in body weight, glucose markers, and cardiometabolic parameters.
Some studies also noted gastrointestinal-related observations, such as nausea and changes in bowel patterns, which are commonly monitored in metabolic peptide research. Imaging-based assessments in liver health studies have shown measurable changes in liver fat content over time.
However, these findings are based on controlled experimental and clinical research settings. Outcomes vary depending on study design, population, and dosing parameters, and continue to be evaluated in ongoing research programs.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
Subscribe for exclusive offers and updates on new arrivals